March 18, 2024: NCHR was one of 6 Consumer Safety groups submitting joint comments to the Consumer Product Safety Commission (CPSC) for its Proposed Rule for Safety Standards for Infant Support C...
https://www.center4research.org/consumer-comment-cpsc-infant-support-cushions/
Medscape March 14, 2024: What patients should know about OTC birth control pill Opill, which will be available in March 2024. How can we make sure patients know the risks and use it correctly and...
https://www.center4research.org/medscape-otc-opill-contraceptive-available/
Washington Post, March 16, 2024: New study results showing that the ALS drug Relyvrio does not work raises important questions about FDA’s decision to be flexible about approval even when the s...
https://www.center4research.org/relyvrio-als-ineffective-2024/
March 15, 2024: NCHR provided testimony at the Presidential Advisory Council Meeting on Combating Antimicrobial Resistance. We advised that AMR research should move away from using pathogen-speci...
NCHR supports the proposed FDA rule, which aims to reclassify wound dressings and liquid wound washes containing antimicrobials based on their level of antimicrobial resistance (AMR), with higher...
https://www.center4research.org/nchr-comment-wound-dressings/
March 7, 2024 article by Association of Health Care Journalists explains the problems with the FDA accelerated approval process and gives advice on how to cover the evidence accurately. NCHR’s ...
https://www.center4research.org/ahcj-journalists-accelerated-approval-pepaxto/
September 7, 2022 Diana Zuckerman testified on behalf of NCHR at the FDA Advisory Committee hearing about the poor evidence foe Amylyx drug AMX0035 for the treatment of ALS, and how approving thi...
Inside Health Policy, March 4, 2024: NCHR was interviewed regarding the FDA rescinding accelerated approval for Pepaxto for multiple myeloma. We explain that the FDA’s new “’streamlined’ ...
https://www.center4research.org/fda-rescind-accelerated-approval-pepaxto/
February 28, 2024: NCHR provided written testimony to the Maryland House of Delegates Environment and Transportation Committee in support of HB1147, a bill to prohibit the sale and installation o...
https://www.center4research.org/nchr-testimony-maryland-hb1147-playground-prohibitions/
February 16, 2024: NCHR provides written testimony to the Maryland House of Delegates Environment and Transportation Committee to support HB457, which requires transparency regarding all new arti...
https://www.center4research.org/nchr-testimony-maryland-hb457-chain-of-custody-2024/